



DAC

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:  
Rosen et al.

Docket No.: PS805

Application No.: 09/950,083

Art Unit: 1634

MAY 17 2004

Filed: September 12, 2001

OFF

For: HUMAN SECRETED PROTEINS

Examiner: M. Sheinberg

**PETITION UNDER 37 C.F.R. §§ 1.181(a)(3) AND/OR 1.182 TO OBTAIN  
CERTIFIED COPIES OF THE APPLICATION AS FILED ON COMPACT DISC**

**MS Petition**

**Attention: Mr. Jay Lucas**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Applicants respectfully petition for the USPTO to provide certified copies of the instant application as filed on compact disc. Applicants have been required to submit such certified copies to the European Patent Office for related European patent applications which claim priority to the instant application through the Paris Convention and the Patent Cooperation Treaty. Applicants have sought to obtain certified copies through the Office of Public Records using ordinary procedures, but have been unsuccessful due to the extreme size of the application. In order to prevent the loss of Applicants' priority claims to the instant application, Applicants hereby request that the Office provide certified copies of the instant application as filed on compact disc.

In support of this request, Applicants submit the following:

1. The instant application was properly filed on September 12, 2001. The application as filed contains a specification of about 4546 pages and a sequence listing of about 12317 pages, as well as a fee transmittal form, patent application transmittal letter, executed Declaration, Statement Under 37 CFR 1.821(f), Transmittal and Submission under 37 CFR 1.824 and 1.52(e)(3)(ii), and Assignment Recordation Cover sheet with Executed Assignment. *See* Copy of Official Filing Receipt (Exhibit A); Date-Stamped Postcard indicating receipt by OIPE on September 12, 2001 and Serial Number Postcard (Exhibit B).
2. Applicants have filed International Applications claiming priority to the instant application, including, for example, PCT/US02/09135, filed on March 26, 2002.

## ARTIFACT SHEET

Enter artifact number below. Artifact number is application number + artifact type code (see list below) + sequential letter (A, B, C ...). The first artifact folder for an artifact type receives the letter A, the second B, etc.. Examples: 59123456PA, 59123456PB, 59123456ZA, 59123456ZB

Indicate quantity of a single type of artifact received but not scanned. Create individual artifact folder/box and artifact number for each Artifact Type.

<input type="checkbox"/>	CD(s) containing:	<input type="checkbox"/>
	computer program listing	
	Doc Code: Computer	Artifact Type Code: P
	pages of specification	
	and/or sequence listing	<input type="checkbox"/>
	and/or table	
	Doc Code: Artifact	Artifact Type Code: S
	content unspecified or combined	<input type="checkbox"/>
	Doc Code: Artifact	Artifact Type Code: U

<input type="checkbox"/>	Stapled Set(s) Color Documents or B/W Photographs
	Doc Code: Artifact    Artifact Type Code: C

<input type="checkbox"/>	Microfilm(s)
	Doc Code: Artifact    Artifact Type Code: F

<input type="checkbox"/>	Video tape(s)
	Doc Code: Artifact    Artifact Type Code: V

<input type="checkbox"/>	Model(s)
	Doc Code: Artifact    Artifact Type Code: M


<input type="checkbox"/>	Bound Document(s)
	Doc Code: Artifact    Artifact Type Code: B

<input type="checkbox"/>	Confidential Information Disclosure Statement or Other Documents marked Proprietary, Trade Secrets, Subject to Protective Order, Material Submitted under MPEP 724.02, etc.
	Doc Code: Artifact    Artifact Type Code X

<input type="checkbox"/>	Other, description: _____
	Doc Code: Artifact    Artifact Type Code: Z

3. When International Application No. PCT/US02/09135 was filed with the U.S. Receiving Office, Applicants requested and paid for a certified copy of the instant application as filed to be prepared and transmitted to the International Bureau by the USPTO in its capacity as the U.S. Receiving Office. *See* PCT Request, Box VI (Exhibit C).
4. The International Bureau never received a certified copy of the instant application. *See* EPO Form 1111 from EP Application No. 02756084.6-2405, the EP national stage of International Application No. PCT/US02/09135 (Exhibit D). As indicated therein, the right to priority will be lost unless the certified copy is filed.
5. Attorneys for Applicants have contacted the Office of Public Records to obtain an additional certified copy of the application as filed through normal channels pursuant to 37 C.F.R. §§ 1.13 and 1.19(b)(1), but were informed after telephone inquiries that due to the large size of the application, only 100 pages would be produced and certified if a request for a certified copy was filed.
6. Attorneys for Applicants have been notified by the European Patent Office that certified copies of priority documents containing only the first 100 pages of the document are not acceptable, rendering the Office of Public Records proposal unworkable. As stated in Exhibit D, an "exact copy" is required. Moreover, Attorneys for Applicants are unaware of any authority allowing the Office of Public Records to provide only a partial certified copy when a certified copy of an entire application as filed has been requested.
7. Pursuant to 1278 OG 261, "Copies of File Contents Available on Compact Disc-Partial Waiver of 37 CFR 1.19(b)" (January 27, 2004), copies from the USPTO files may be supplied as electronic files on compact disc regardless of the media on which those records were originally submitted to the Office.
8. Attorneys for Applicants have been advised that for large applications for which certified copies are not otherwise obtainable from the USPTO, Applicants may submit copies of the application as filed in electronic form on compact disc, together with a petition and a statement that the files are the same as the application as filed. The Office will then certify the compact disc copies.
9. The undersigned hereby certifies that the content of the electronic files included on the enclosed compact discs is the same as the content of the application as filed.

As the above statements make clear, Applicants have no other available remedy to obtain a certified copy of the instant application. Applicants have previously requested and paid for a certified copy to be prepared and transmitted to the International Bureau, but no copy was ever received by the IB. The U.S. Receiving Office's failure to provide a



MAY 17 2004

OFFICE OF THE COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/950,083	09/12/2001	1646	844	PS-805		23	4

22195

HUMAN GENOME SCIENCES INC  
9410 KEY WEST AVENUE  
ROCKVILLE, MD 20850



RECEIVED

DEC 14 2001

HGS PATENT DEPT.

CONFIRMATION NO. 9454

FILING RECEIPT



\*OC000000007179132\*

Date Mailed: 12/11/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

**Applicant(s)**

Craig A. Rosen, Residence Not Provided;  
Steven M. Ruben, Residence Not Provided;  
George A. Komatsoulis, Residence Not Provided;

**Domestic Priority data as claimed by applicant**

THIS APPLN CLAIMS BENEFIT OF 60/278,650 03/27/2001  
AND A CIP OF 09/833,245 04/12/2001  
AND A CIP OF PCT/US01/11988 04/12/2001  
AND A CIP OF PCT/US00/06043 03/09/2000  
WHICH CLAIMS BENEFIT OF 60/167,061 11/23/1999  
AND CLAIMS BENEFIT OF 60/124,146 03/12/1999  
THIS APPLICATION 09950083  
IS A CIP OF PCT/US00/06012 03/09/2000  
WHICH CLAIMS BENEFIT OF 60/166,989 11/23/1999  
AND CLAIMS BENEFIT OF 60/124,093 03/12/1999  
THIS APPLICATION 09950083  
IS A CIP OF PCT/US00/06058 03/09/2000  
WHICH CLAIMS BENEFIT OF 60/168,654 12/03/1999  
AND CLAIMS BENEFIT OF 60/124,145 03/12/1999  
THIS APPLICATION 09950083  
IS A CIP OF PCT/US00/06044 03/09/2000  
WHICH CLAIMS BENEFIT OF 60/168,661 12/03/1999  
AND CLAIMS BENEFIT OF 60/124,099 03/12/1999  
THIS APPLICATION 09950083  
IS A CIP OF PCT/US00/06059 03/09/2000  
WHICH CLAIMS BENEFIT OF 60/168,622 12/03/1999  
AND CLAIMS BENEFIT OF 60/124,096 03/12/1999  
THIS APPLICATION 09950083  
IS A CIP OF PCT/US00/06042 03/09/2000

WHICH CLAIMS BENEFIT OF 60/168,663 12/03/1999  
AND CLAIMS BENEFIT OF 60/124,143 03/12/1999  
THIS APPLICATION 09950083  
IS A CIP OF PCT/US00/06014 03/09/2000  
WHICH CLAIMS BENEFIT OF 60/168,665 12/03/1999  
AND CLAIMS BENEFIT OF 60/138,598 06/11/1999  
AND CLAIMS BENEFIT OF 60/124,095 03/12/1999  
THIS APPLICATION 09950083  
IS A CIP OF PCT/US00/06013 03/09/2000  
WHICH CLAIMS BENEFIT OF 60/168,662 12/03/1999  
AND CLAIMS BENEFIT OF 60/138,626 06/11/1999  
AND CLAIMS BENEFIT OF 60/125,360 03/19/1999  
THIS APPLICATION 09950083  
IS A CIP OF PCT/US00/06049 03/09/2000  
WHICH CLAIMS BENEFIT OF 60/168,667 12/03/1999  
AND CLAIMS BENEFIT OF 60/138,574 06/11/1999  
AND CLAIMS BENEFIT OF 60/124,444 03/15/1999  
THIS APPLICATION 09950083  
IS A CIP OF PCT/US00/06057 03/09/2000  
WHICH CLAIMS BENEFIT OF 60/168,666 12/03/1999  
AND CLAIMS BENEFIT OF 60/138,597 06/11/1999  
AND CLAIMS BENEFIT OF 60/124,142 03/12/1999  
THIS APPLICATION 09950083  
IS A CIP OF PCT/US00/06824 03/16/2000  
WHICH CLAIMS BENEFIT OF 60/168,664 12/03/1999  
AND CLAIMS BENEFIT OF 60/125,359 03/19/1999  
THIS APPLICATION 09950083  
IS A CIP OF PCT/US00/06765 03/16/2000  
WHICH CLAIMS BENEFIT OF 60/169,906 12/10/1999  
AND CLAIMS BENEFIT OF 60/126,051 03/23/1999  
THIS APPLICATION 09950083  
IS A CIP OF PCT/US00/06792 03/16/2000  
WHICH CLAIMS BENEFIT OF 60/169,980 12/10/1999  
AND CLAIMS BENEFIT OF 60/125,362 03/19/1999  
THIS APPLICATION 09950083  
IS A CIP OF PCT/US00/06830 03/16/2000  
WHICH CLAIMS BENEFIT OF 60/169,910 12/10/1999  
AND CLAIMS BENEFIT OF 60/125,361 03/19/1999  
THIS APPLICATION 09950083  
IS A CIP OF PCT/US00/06782 03/16/2000  
AND SAID  
CLAIMS BENEFIT OF 60/169,936 12/10/1999  
AND CLAIMS BENEFIT OF 60/125,812 03/23/1999  
THIS APPLICATION 09950083  
IS A CIP OF PCT/US00/06822 03/16/2000  
WHICH CLAIMS BENEFIT OF 60/169,916 12/10/1999  
AND CLAIMS BENEFIT OF 60/126,054 03/23/1999  
THIS APPLICATION 09950083  
IS A CIP OF PCT/US00/06791 03/16/2000  
WHICH CLAIMS BENEFIT OF 60/169,946 12/10/1999  
AND CLAIMS BENEFIT OF 60/125,815 03/23/1999  
THIS APPLICATION 09950083  
IS A CIP OF PCT/US00/06828 03/16/2000  
WHICH CLAIMS BENEFIT OF 60/169,616 12/08/1999  
AND CLAIMS BENEFIT OF 60/125,358 03/19/1999  
THIS APPLICATION 09950083  
IS A CIP OF PCT/US00/06823 03/16/2000  
WHICH CLAIMS BENEFIT OF 60/169,623 12/08/1999  
AND CLAIMS BENEFIT OF 60/125,364 03/19/1999  
THIS APPLICATION 09950083

IS A CIP OF PCT/US00/06781 03/16/2000  
WHICH CLAIMS BENEFIT OF 60/169,617 12/08/1999  
AND CLAIMS BENEFIT OF 60/125,363 03/19/1999  
THIS APPLICATION 09950083

IS A CIP OF PCT/US00/07505 03/22/2000  
WHICH CLAIMS BENEFIT OF 60/172,410 12/17/1999  
AND CLAIMS BENEFIT OF 60/126,502 03/26/1999  
THIS APPLICATION 09950083

IS A CIP OF PCT/US00/07440 03/22/2000  
WHICH CLAIMS BENEFIT OF 60/172,409 12/17/1999  
AND CLAIMS BENEFIT OF 60/126,503 03/26/1999  
THIS APPLICATION 09950083

IS A CIP OF PCT/US00/07506 03/22/2000  
WHICH CLAIMS BENEFIT OF 60/172,412 12/17/1999  
AND CLAIMS BENEFIT OF 60/126,505 03/26/1999  
THIS APPLICATION 09950083

IS A CIP OF PCT/US00/07507 03/22/2000  
WHICH CLAIMS BENEFIT OF 60/172,408 12/17/1999  
AND CLAIMS BENEFIT OF 60/126,594 03/26/1999  
THIS APPLICATION 09950083

IS A CIP OF PCT/US00/07535 03/22/2000  
WHICH CLAIMS BENEFIT OF 60/172,413 12/17/1999  
AND CLAIMS BENEFIT OF 60/126,511 03/26/1999  
THIS APPLICATION 09950083

IS A CIP OF PCT/US00/07525 03/22/2000  
WHICH CLAIMS BENEFIT OF 60/171,549 12/22/1999  
AND CLAIMS BENEFIT OF 60/126,595 03/26/1999  
THIS APPLICATION 09950083

IS A CIP OF PCT/US00/07534 03/22/2000  
WHICH CLAIMS BENEFIT OF 60/171,504 12/22/1999  
AND CLAIMS BENEFIT OF 60/126,598 03/26/1999  
THIS APPLICATION 09950083

IS A CIP OF PCT/US00/07483 03/22/2000  
WHICH CLAIMS BENEFIT OF 60/171,552 12/22/1999  
AND CLAIMS BENEFIT OF 60/126,596 03/26/1999  
THIS APPLICATION 09950083

IS A CIP OF PCT/US00/07526 03/22/2000  
WHICH CLAIMS BENEFIT OF 60/171,550 12/22/1999  
AND CLAIMS BENEFIT OF 60/126,600 03/26/1999  
THIS APPLICATION 09950083

IS A CIP OF PCT/US00/07527 03/22/2000  
WHICH CLAIMS BENEFIT OF 60/171,551 12/22/1999  
AND CLAIMS BENEFIT OF 60/126,501 03/26/1999  
THIS APPLICATION 09950083

IS A CIP OF PCT/US00/07661 03/23/2000  
WHICH CLAIMS BENEFIT OF 60/174,847 01/07/2000  
AND CLAIMS BENEFIT OF 60/126,504 03/26/1999  
THIS APPLICATION 09950083

IS A CIP OF PCT/US00/07579 03/23/2000  
WHICH CLAIMS BENEFIT OF 60/174,853 01/07/2000  
AND CLAIMS BENEFIT OF 60/126,509 03/26/1999  
THIS APPLICATION 09950083

IS A CIP OF PCT/US00/07723 03/23/2000  
WHICH CLAIMS BENEFIT OF 60/242,710 10/25/2000  
AND CLAIMS BENEFIT OF 60/174,852 01/07/2000  
THIS APPLICATION 09950083

IS A CIP OF PCT/US00/07724 03/23/2000  
WHICH CLAIMS BENEFIT OF 60/174,850 01/07/2000  
AND CLAIMS BENEFIT OF 60/126,510 03/26/1999  
THIS APPLICATION 09950083

IS A CIP OF PCT/US00/14929 06/01/2000  
WHICH CLAIMS BENEFIT OF 60/174,851 01/07/2000  
AND CLAIMS BENEFIT OF 60/138,573 06/11/1999  
THIS APPLICATION 09950083  
IS A CIP OF PCT/US00/07722 03/23/2000  
WHICH CLAIMS BENEFIT OF 60/174,871 01/07/2000  
AND CLAIMS BENEFIT OF 60/126,508 03/26/1999  
THIS APPLICATION 09950083  
IS A CIP OF PCT/US00/07578 03/23/2000  
WHICH CLAIMS BENEFIT OF 60/174,872 01/07/2000  
AND CLAIMS BENEFIT OF 60/126,507 03/26/1999  
THIS APPLICATION 09950083  
IS A CIP OF PCT/US00/07726 03/23/2000  
WHICH CLAIMS BENEFIT OF 60/174,877 01/07/2000  
AND CLAIMS BENEFIT OF 60/126,597 03/26/1999  
THIS APPLICATION 09950083  
IS A CIP OF PCT/US00/07677 03/23/2000  
WHICH CLAIMS BENEFIT OF 60/176,064 01/14/2000  
AND CLAIMS BENEFIT OF 60/154,373 09/17/1999  
AND CLAIMS BENEFIT OF 60/126,601 03/26/1999  
THIS APPLICATION 09950083  
IS A CIP OF PCT/US00/07725 03/23/2000  
WHICH CLAIMS BENEFIT OF 60/176,063 01/14/2000  
AND CLAIMS BENEFIT OF 60/126,602 03/26/1999  
THIS APPLICATION 09950083  
IS A CIP OF PCT/US00/09070 04/06/2000  
WHICH CLAIMS BENEFIT OF 60/176,052 01/14/2000  
AND CLAIMS BENEFIT OF 60/128,695 04/09/1999  
THIS APPLICATION 09950083  
IS A CIP OF PCT/US00/08982 04/06/2000  
WHICH CLAIMS BENEFIT OF 60/176,069 01/14/2000  
AND CLAIMS BENEFIT OF 60/128,696 04/09/1999  
THIS APPLICATION 09950083  
IS A CIP OF PCT/US00/08983 04/06/2000  
WHICH CLAIMS BENEFIT OF 60/176,068 01/14/2000  
AND CLAIMS BENEFIT OF 60/128,703 04/09/1999  
THIS APPLICATION 09950083  
IS A CIP OF PCT/US00/09067 04/06/2000  
WHICH CLAIMS BENEFIT OF 60/176,929 01/20/2000  
AND CLAIMS BENEFIT OF 60/128,697 04/09/1999  
THIS APPLICATION 09950083  
IS A CIP OF PCT/US00/09066 04/06/2000  
WHICH CLAIMS BENEFIT OF 60/176,926 01/20/2000  
AND CLAIMS BENEFIT OF 60/128,698 04/09/1999  
THIS APPLICATION 09950083  
IS A CIP OF PCT/US00/09068 04/06/2000  
WHICH CLAIMS BENEFIT OF 60/177,050 01/20/2000  
AND CLAIMS BENEFIT OF 60/128,699 04/09/1999  
THIS APPLICATION 09950083  
IS A CIP OF PCT/US00/08981 04/06/2000  
WHICH CLAIMS BENEFIT OF 60/177,166 01/20/2000  
AND CLAIMS BENEFIT OF 60/128,701 04/09/1999  
THIS APPLICATION 09950083  
IS A CIP OF PCT/US00/08980 04/06/2000  
AND SAID  
CLAIMS BENEFIT OF 60/176,930 01/20/2000  
AND CLAIMS BENEFIT OF 60/128,700 04/09/1999  
THIS APPLICATION 09950083  
IS A CIP OF PCT/US00/09071 04/06/2000  
WHICH CLAIMS BENEFIT OF 60/176,931 01/20/2000

AND CLAIMS BENEFIT QF 60/128,694 04/09/1999  
 THIS APPLICATION 09950083  
 IS A CIP OF PCT/US00/09069 04/06/2000  
 WHICH CLAIMS BENEFIT OF 60/177,049 01/20/2000  
 AND CLAIMS BENEFIT OF 60/128,702 04/09/1999  
 THIS APPLICATION 09950083  
 IS A CIP OF PCT/US00/15136 06/01/2000  
 WHICH CLAIMS BENEFIT OF 60/138,629 06/11/1999  
 THIS APPLICATION 09950083  
 IS A CIP OF PCT/US00/14926 06/01/2000  
 WHICH CLAIMS BENEFIT OF 60/138,628 06/11/1999  
 THIS APPLICATION 09950083  
 IS A CIP OF PCT/US00/14963 06/01/2000  
 WHICH CLAIMS BENEFIT OF 60/138,631 06/11/1999  
 THIS APPLICATION 09950083  
 IS A CIP OF PCT/US00/15135 06/01/2000  
 WHICH CLAIMS BENEFIT OF 60/138,632 06/11/1999  
 THIS APPLICATION 09950083  
 IS A CIP OF PCT/US00/14934 06/01/2000  
 WHICH CLAIMS BENEFIT OF 60/138,599 06/11/1999  
 THIS APPLICATION 09950083  
 IS A CIP OF PCT/US00/14933 06/01/2000  
 WHICH CLAIMS BENEFIT OF 60/138,572 06/11/1999  
 THIS APPLICATION 09950083  
 IS A CIP OF PCT/US00/15137 06/01/2000  
 WHICH CLAIMS BENEFIT OF 60/138,625 06/11/1999  
 THIS APPLICATION 09950083  
 IS A CIP OF PCT/US00/14928 06/01/2000  
 WHICH CLAIMS BENEFIT OF 60/138,633 06/11/1999  
 THIS APPLICATION 09950083  
 IS A CIP OF PCT/US00/14973 06/01/2000  
 WHICH CLAIMS BENEFIT OF 60/138,630 06/11/1999  
 THIS APPLICATION 09950083  
 IS A CIP OF PCT/US00/14964 06/01/2000  
 WHICH CLAIMS BENEFIT OF 60/138,627 06/11/1999  
 THIS APPLICATION 09950083  
 IS A CIP OF PCT/US00/26376 09/26/2000  
 WHICH CLAIMS BENEFIT OF 60/155,808 09/27/1999  
 THIS APPLICATION 09950083  
 IS A CIP OF PCT/US00/26371 09/26/2000  
 WHICH CLAIMS BENEFIT OF 60/155,804 09/27/1999  
 THIS APPLICATION 09950083  
 IS A CIP OF PCT/US00/26324 09/26/2000  
 WHICH CLAIMS BENEFIT OF 60/155,807 09/27/1999  
 THIS APPLICATION 09950083  
 IS A CIP OF PCT/US00/26323 09/26/2000  
 WHICH CLAIMS BENEFIT OF 60/155,805 09/27/1999  
 THIS APPLICATION 09950083  
 IS A CIP OF PCT/US00/26337 09/26/2000  
 WHICH CLAIMS BENEFIT OF 60/155,806 09/27/1999  
 THIS APPLICATION 09950083  
 IS A CIP OF PCT/US01/13318 04/26/2001  
 WHICH CLAIMS BENEFIT OF 60/212,142 06/16/2000  
 AND CLAIMS BENEFIT OF 60/201,194 05/02/2000

#### Foreign Applications

If Required, Foreign Filing License Granted 12/10/2001



**Projected Publication Date:** 03/21/2002

**Non-Publication Request:** No

**Early Publication Request:** No

**Title**

Human secreted proteins

**Preliminary Class**

514

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).



PLEASE HOLD FERT SERIAL NUMBER

Please date stamp and return to addressee on reverse side


Applicants: ROSEN, et al.

Docket No. PS-805

Application No.: Unassigned

Filed: herewith

Title: Human Secreted Proteins



Documents Filed Via Hand Delivery on September 12, 2001

1. Postcards (2);
2. Utility Patent Application Transmittal w/ 4,546 pgs. spec., (incl. 23. claims (4 pgs.), Abstract (1 pg.)); and Sequence Listing in paper (12,317 pgs.) and computer-readable (CRF) form; and Executed Declaration (4 pgs.);
3. Fee Transmittal Sheet, with appropriate fee(s) (in dupl.);
4. Statement Under 37 CFR 1.821(f);
5. Transmittal and Submission Under 37 C.F.R. §§ 1.824 and 1.52(e)(3)(ii); and
6. Assignment Recordation Form Cover Sheet and Executed Assignment (2 pgs.).

KKH/DS/lcc

Attn.: Legal Dept.

HUMAN GENOME SCIENCES, INC.

# PCT

## REQUEST

The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty.

For receiving Office use only

International Application No.

International Filing Date

Name of receiving Office and "PCT International Application"

Applicant's or agent's file reference  
(if desired) (12 characters maximum) PS956PCT

**Box No. I TITLE OF INVENTION**  
HUMAN SECRETED PROTEINS

**Box No. II APPLICANT** ☐ This person is also inventor

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

Human Genome Sciences, Inc.  
9410 Key West Avenue  
Rockville, Maryland 20850  
United States of America

Telephone No.  
301-309-8504

Facsimile No.  
301-309-8439

Teleprinter No.

Applicant's registration No. with the Office

State (that is, country) of nationality:  
US

State (that is, country) of residence:  
US

This person is applicant for the purposes of: ☐ all designated States ☒ all designated States except the United States of America ☐ the United States of America only ☐ the States indicated in the Supplemental Box

**Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)**

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

ROSEN, Craig A.  
22400 Rolling Hill Lane  
Laytonsville, Maryland 20882  
United States of America

This person is:

☐ applicant only  
☒ applicant and inventor  
☐ inventor only (If this check-box is marked, do not fill in below.)

Applicant's registration No. with the Office

State (that is, country) of nationality:  
US

State (that is, country) of residence:  
US

This person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

☐ Further applicants and/or (further) inventors are indicated on a continuation sheet.

**Box No. IV AGENT OR COMMON REPRESENTATIVE; OR ADDRESS FOR CORRESPONDENCE**

The person identified below is hereby/has been appointed to act on behalf of the applicant(s) before the competent International Authorities as: ☒ agent ☐ common representative

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)

HOOVER, Kenley K.  
Human Genome Sciences, Inc.  
9410 Key West Avenue  
Rockville, Maryland 20850

Telephone No.  
301-610-5771

Facsimile No.  
301-309-8439

Teleprinter No.

Agent's registration No. with the Office  
40,302

☐ Address for correspondence: Mark this check-box where no agent or common representative is/has been appointed and the space above is used instead to indicate a special address to which correspondence should be sent.

**Continuation of Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)***If none of the following sub-boxes is used, this sheet should not be included in the request.*

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

RUBEN, Steven M.  
18528 Heritage Hills Drive  
Olney, MD 20832  
United States of America

This person is:

- ☐ applicant only  
☒ applicant and inventor  
☐ inventor only (If this check-box is marked, do not fill in below.)

Applicant's registration No. with the Office

State (that is, country) of nationality:  
US

State (that is, country) of residence:  
US

This person is applicant for the purposes of:

- ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

This person is:

- ☐ applicant only  
☐ applicant and inventor  
☐ inventor only (If this check-box is marked, do not fill in below.)

Applicant's registration No. with the Office

State (that is, country) of nationality:

State (that is, country) of residence:

This person is applicant for the purposes of:

- ☐ all designated States ☐ all designated States except the United States of America ☐ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

This person is:

- ☐ applicant only  
☐ applicant and inventor  
☐ inventor only (If this check-box is marked, do not fill in below.)

Applicant's registration No. with the Office

State (that is, country) of nationality:

State (that is, country) of residence:

This person is applicant for the purposes of:

- ☐ all designated States ☐ all designated States except the United States of America ☐ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

This person is:

- ☐ applicant only  
☐ applicant and inventor  
☐ inventor only (If this check-box is marked, do not fill in below.)

Applicant's registration No. with the Office

State (that is, country) of nationality:

State (that is, country) of residence:

This person is applicant for the purposes of:

- ☐ all designated States ☐ all designated States except the United States of America ☐ the United States of America only ☐ the States indicated in the Supplemental Box

☐ Further applicants and/or (further) inventors are indicated on another continuation sheet.

Box No.V DESIGNATION OF STATES' Mark the applicable check-boxes below; at least one must be marked.

The following designations are hereby made under Rule 4.9(a):

**Regional Patent**

- ☒ **AP ARIPO Patent:** GH Ghana, GM Gambia, KE Kenya, LS Lesotho, MW Malawi, MZ Mozambique, SD Sudan, SL Sierra Leone, SZ Swaziland, TZ United Republic of Tanzania, UG Uganda, ZW Zimbabwe, and any other State which is a Contracting State of the Harare Protocol and of the PCT
- ☒ **EA Eurasian Patent:** AM Armenia, AZ Azerbaijan, BY Belarus, KG Kyrgyzstan, KZ Kazakhstan, MD Republic of Moldova, RU Russian Federation, TJ Tajikistan, TM Turkmenistan, and any other State which is a Contracting State of the Eurasian Patent Convention and of the PCT
- ☒ **EP European Patent:** AT Austria, BE Belgium, CH & LI Switzerland and Liechtenstein, CY Cyprus, DE Germany, DK Denmark, ES Spain, FI Finland, FR France, GB United Kingdom, GR Greece, IE Ireland, IT Italy, LU Luxembourg, MC Monaco, NL Netherlands, PT Portugal, SE Sweden, TR Turkey, and any other State which is a Contracting State of the European Patent Convention and of the PCT
- ☒ **OA OAPI Patent:** BF Burkina Faso, BJ Benin, CF Central African Republic, CG Congo, CI Côte d'Ivoire, CM Cameroon, GA Gabon, GN Guinea, GW Guinea-Bissau, ML Mali, MR Mauritania, NE Niger, SN Senegal, TD Chad, TG Togo, and any other State which is a member State of OAPI and a Contracting State of the PCT (if other kind of protection or treatment desired, specify on dotted line) .....

**National Patent** (if other kind of protection or treatment desired, specify on dotted line):

- |                                                                           |                                                                                        |                                                                       |
|---------------------------------------------------------------------------|----------------------------------------------------------------------------------------|-----------------------------------------------------------------------|
| <input checked="" type="checkbox"/> AE United Arab Emirates               | <input checked="" type="checkbox"/> GE Georgia .....                                   | <input checked="" type="checkbox"/> MW Malawi .....                   |
| <input checked="" type="checkbox"/> AG Antigua and Barbuda                | <input checked="" type="checkbox"/> GH Ghana .....                                     | <input checked="" type="checkbox"/> MX Mexico .....                   |
| <input checked="" type="checkbox"/> AL Albania .....                      | <input checked="" type="checkbox"/> GM Gambia .....                                    | <input checked="" type="checkbox"/> MZ Mozambique .....               |
| <input checked="" type="checkbox"/> AM Armenia .....                      | <input checked="" type="checkbox"/> HR Croatia .....                                   | <input checked="" type="checkbox"/> NO Norway .....                   |
| <input checked="" type="checkbox"/> AT Austria .....                      | <input checked="" type="checkbox"/> HU Hungary .....                                   | <input checked="" type="checkbox"/> NZ New Zealand .....              |
| <input checked="" type="checkbox"/> AU Australia .....                    | <input checked="" type="checkbox"/> ID Indonesia .....                                 | <input checked="" type="checkbox"/> PL Poland .....                   |
| <input checked="" type="checkbox"/> AZ Azerbaijan .....                   | <input checked="" type="checkbox"/> IL Israel .....                                    | <input checked="" type="checkbox"/> PT Portugal .....                 |
| <input checked="" type="checkbox"/> BA Bosnia and Herzegovina .....       | <input checked="" type="checkbox"/> IN India .....                                     | <input checked="" type="checkbox"/> RO Romania .....                  |
| .....                                                                     | <input checked="" type="checkbox"/> IS Iceland .....                                   | <input checked="" type="checkbox"/> RU Russian Federation .....       |
| <input checked="" type="checkbox"/> BB Barbados .....                     | <input checked="" type="checkbox"/> JP Japan .....                                     | .....                                                                 |
| <input checked="" type="checkbox"/> BG Bulgaria .....                     | <input checked="" type="checkbox"/> KE Kenya .....                                     | <input checked="" type="checkbox"/> SD Sudan .....                    |
| <input checked="" type="checkbox"/> BR Brazil .....                       | <input checked="" type="checkbox"/> KG Kyrgyzstan .....                                | <input checked="" type="checkbox"/> SE Sweden .....                   |
| <input checked="" type="checkbox"/> BY Belarus .....                      | <input checked="" type="checkbox"/> KP Democratic People's Republic of Korea .....     | <input checked="" type="checkbox"/> SG Singapore .....                |
| <input checked="" type="checkbox"/> BZ Belize .....                       | <input checked="" type="checkbox"/> KR Republic of Korea .....                         | <input checked="" type="checkbox"/> SI Slovenia .....                 |
| <input checked="" type="checkbox"/> CA Canada .....                       | <input checked="" type="checkbox"/> KZ Kazakhstan .....                                | <input checked="" type="checkbox"/> SK Slovakia .....                 |
| <input checked="" type="checkbox"/> CH & LI Switzerland and Liechtenstein | <input checked="" type="checkbox"/> LC Saint Lucia .....                               | <input checked="" type="checkbox"/> SL Sierra Leone .....             |
| <input checked="" type="checkbox"/> CN China .....                        | <input checked="" type="checkbox"/> LK Sri Lanka .....                                 | <input checked="" type="checkbox"/> TJ Tajikistan .....               |
| <input checked="" type="checkbox"/> CO Colombia .....                     | <input checked="" type="checkbox"/> LR Liberia .....                                   | <input checked="" type="checkbox"/> TM Turkmenistan .....             |
| <input checked="" type="checkbox"/> CR Costa Rica .....                   | <input checked="" type="checkbox"/> LS Lesotho .....                                   | <input checked="" type="checkbox"/> TR Turkey .....                   |
| <input checked="" type="checkbox"/> CU Cuba .....                         | <input checked="" type="checkbox"/> LT Lithuania .....                                 | <input checked="" type="checkbox"/> TT Trinidad and Tobago .....      |
| <input checked="" type="checkbox"/> CZ Czech Republic .....               | <input checked="" type="checkbox"/> LU Luxembourg .....                                | .....                                                                 |
| <input checked="" type="checkbox"/> DE Germany .....                      | <input checked="" type="checkbox"/> LV Latvia .....                                    | <input checked="" type="checkbox"/> TZ United Republic of Tanzania    |
| <input checked="" type="checkbox"/> DK Denmark .....                      | <input checked="" type="checkbox"/> MA Morocco .....                                   | <input checked="" type="checkbox"/> UA Ukraine .....                  |
| <input checked="" type="checkbox"/> DM Dominica .....                     | <input checked="" type="checkbox"/> MD Republic of Moldova .....                       | <input checked="" type="checkbox"/> UG Uganda .....                   |
| <input checked="" type="checkbox"/> DZ Algeria .....                      | .....                                                                                  | <input checked="" type="checkbox"/> US United States of America ..... |
| <input checked="" type="checkbox"/> EE Estonia .....                      | <input checked="" type="checkbox"/> MG Madagascar .....                                | <input checked="" type="checkbox"/> UZ Uzbekistan .....               |
| <input checked="" type="checkbox"/> ES Spain .....                        | <input checked="" type="checkbox"/> MK The former Yugoslav Republic of Macedonia ..... | <input checked="" type="checkbox"/> VN Viet Nam .....                 |
| <input checked="" type="checkbox"/> FI Finland .....                      | <input checked="" type="checkbox"/> MN Mongolia .....                                  | <input checked="" type="checkbox"/> YU Yugoslavia .....               |
| <input checked="" type="checkbox"/> GB United Kingdom .....               | .....                                                                                  | <input checked="" type="checkbox"/> ZA South Africa .....             |
| <input checked="" type="checkbox"/> GD Grenada .....                      | .....                                                                                  | <input checked="" type="checkbox"/> ZW Zimbabwe .....                 |

Check-boxes below reserved for designating States which have become party to the PCT after issuance of this sheet:

<input type="checkbox"/> .....	<input type="checkbox"/> .....	<input type="checkbox"/> .....
<input type="checkbox"/> .....	<input type="checkbox"/> .....	<input type="checkbox"/> .....

**Precautionary Designation Statement:** In addition to the designations made above, the applicant also makes under Rule 4.9(b) all other designations which would be permitted under the PCT except any designation(s) indicated in the Supplemental Box as being excluded from the scope of this statement. The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit. (Confirmation (including fees) must reach the receiving Office within the 15-month time limit.)

**Supplemental Box***If the Supplemental Box is not used, this sheet should not be included in the request.*

1. *If, in any of the Boxes, except Boxes Nos. VIII(i) to (v) for which a special continuation box is provided, the space is insufficient to furnish all the information: in such case, write "Continuation of Box No...." (indicate the number of the Box) and furnish the information in the same manner as required according to the captions of the Box in which the space was insufficient, in particular:*
  - (i) *if more than two persons are to be indicated as applicants and/or inventors and no "continuation sheet" is available: in such case, write "Continuation of Box No. III" and indicate for each additional person the same type of information as required in Box No. III. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below;*
  - (ii) *if, in Box No. II or in any of the sub-boxes of Box No. III, the indication "the States indicated in the Supplemental Box" is checked: in such case, write "Continuation of Box No. II" or "Continuation of Box No. III" or "Continuation of Boxes No. II and No. III" (as the case may be), indicate the name of the applicant(s) involved and, next to (each) such name, the State(s) (and/or, where applicable, ARIPO, Eurasian, European or OAPI patent) for the purposes of which the named person is applicant;*
  - (iii) *if, in Box No. II or in any of the sub-boxes of Box No. III, the inventor or the inventor/applicant is not inventor for the purposes of all designated States or for the purposes of the United States of America: in such case, write "Continuation of Box No. II" or "Continuation of Box No. III" or "Continuation of Boxes No. II and No. III" (as the case may be), indicate the name of the inventor(s) and, next to (each) such name, the State(s) (and/or, where applicable, ARIPO, Eurasian, European or OAPI patent) for the purposes of which the named person is inventor;*
  - (iv) *if, in addition to the agent(s) indicated in Box No. IV, there are further agents: in such case, write "Continuation of Box No. IV" and indicate for each further agent the same type of information as required in Box No. IV;*
  - (v) *if, in Box No. V, the name of any State (or OAPI) is accompanied by the indication "patent of addition," or "certificate of addition," or if, in Box No. V, the name of the United States of America is accompanied by an indication "continuation" or "continuation-in-part": in such case, write "Continuation of Box No. V" and the name of each State involved (or OAPI), and after the name of each such State (or OAPI), the number of the parent title or parent application and the date of grant of the parent title or filing of the parent application;*
  - (vi) *if, in Box No. VI, there are more than five earlier applications whose priority is claimed: in such case, write "Continuation of Box No. VI" and indicate for each additional earlier application the same type of information as required in Box No. VI.*
2. *If, with regard to the precautionary designation statement contained in Box No. V, the applicant wishes to exclude any State(s) from the scope of that statement: in such case, write "Designation(s) excluded from precautionary designation statement" and indicate the name or two-letter code of each State so excluded.*

**Box No. VI PRIORITY CLAIM**

The priority of the following earlier application(s) is hereby claimed:

Filing date of earlier application (day/month/year)	Number of earlier application	Where earlier application is:		
		national application: country	regional application:* regional Office	international application: receiving Office
item (1) 27 March 2001	60/278,650	US		
item (2) 12 September 2001	09/950,082	US		
item (3) 12 September 2001	09/950,083	US		
item (4)				
item (5)				

☐ Further priority claims are indicated in the Supplemental Box.

The receiving Office is requested to prepare and transmit to the International Bureau a certified copy of the earlier application(s) (only if the earlier application was filed with the Office which for the purposes of this international application is the receiving Office) identified above as:

☒ all items    ☐ item (1)    ☐ item (2)    ☐ item (3)    ☐ item (4)    ☐ item (5)    ☐ other, see Supplemental Box

\* Where the earlier application is an ARIPO application, indicate at least one country party to the Paris Convention for the Protection of Industrial Property or one Member of the World Trade Organization for which that earlier application was filed (Rule 4.10(b)(ii)). . . . .

**Box No. VII INTERNATIONAL SEARCHING AUTHORITY**

**Choice of International Searching Authority (ISA)** (if two or more International Searching Authorities are competent to carry out the international search, indicate the Authority chosen; the two-letter code may be used):

ISA / US

**Request to use results of earlier search; reference to that search** (if an earlier search has been carried out by or requested from the International Searching Authority):

Date (day/month/year)

Number

Country (or regional Office)

**Box No. VIII DECLARATIONS**

The following declarations are contained in Boxes Nos. VIII (i) to (v) (mark the applicable check-boxes below and indicate in the right column the number of each type of declaration):

Number of  
declarations


- |                                             |                                                                                                                                      |   |
|---------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|---|
| <input type="checkbox"/> Box No. VIII (i)   | Declaration as to the identity of the inventor                                                                                       | : |
| <input type="checkbox"/> Box No. VIII (ii)  | Declaration as to the applicant's entitlement, as at the international filing date, to apply for and be granted a patent             | : |
| <input type="checkbox"/> Box No. VIII (iii) | Declaration as to the applicant's entitlement, as at the international filing date, to claim the priority of the earlier application | : |
| <input type="checkbox"/> Box No. VIII (iv)  | Declaration of inventorship (only for the purposes of the designation of the United States of America)                               | : |
| <input type="checkbox"/> Box No. VIII (v)   | Declaration as to non-prejudicial disclosures or exceptions to lack of novelty                                                       | : |

**Box No. IX CHECK LIST; LANGUAGE OF FILING**

This international application contains:		This international application is accompanied by the following item(s) (mark the applicable check-boxes below and indicate in right column the number of each item):		Number of items
(a) the following number of sheets in paper form:		1. <input checked="" type="checkbox"/> fee calculation sheet		1
request (including declaration sheets)	: 6	2. <input type="checkbox"/> original separate power of attorney		
description (excluding sequence listing part)	: 567	3. <input type="checkbox"/> original general power of attorney		
claims	: 10	4. <input checked="" type="checkbox"/> copy of general power of attorney; reference number, if any: .....		3
abstract	: 1	5. <input type="checkbox"/> statement explaining lack of signature		
drawings	: 0	6. <input type="checkbox"/> priority document(s) identified in Box No. VI as item(s): .....		
<b>Sub-total number of sheets</b>	<b>: 584</b>	7. <input type="checkbox"/> translation of international application into (language): .....		
sequence listing part of description (actual number of sheets if filed in paper form, whether or not also filed in computer readable form; see (b) below)	: 278	8. <input type="checkbox"/> separate indications concerning deposited microorganism or other biological material		
<b>Total number of sheets</b>	<b>: 862</b>	9. <input checked="" type="checkbox"/> sequence listing in computer readable form (indicate also type and number of carriers (diskette, CD-ROM, CD-R or other))		
(b) sequence listing part of description filed in computer readable form		(i) <input checked="" type="checkbox"/> copy submitted for the purposes of international search under Rule 13ter only (and not as part of the international application)		1 disk
(i) <input type="checkbox"/> only (under Section 801(a)(i))		(ii) <input type="checkbox"/> (only where check-box (b)(i) or (b)(ii) is marked in left column) additional copies including, where applicable, the copy for the purposes of international search under Rule 13ter		
(ii) <input type="checkbox"/> in addition to being filed in paper form (under Section 801(a)(ii))		(iii) <input type="checkbox"/> together with relevant statement as to the identity of the copy or copies with the sequence listing part mentioned in left column		
<b>Type and number of carriers</b> (diskette, CD-ROM, CD-R or other) on which the sequence listing part is contained (additional copies to be indicated under item 9(ii), in right column): .....		10. <input type="checkbox"/> other (specify): .....		
<b>Figure of the drawings</b> which should accompany the abstract:		<b>Language of filing of the international application:</b> English		

**Box No. X SIGNATURE OF APPLICANT, AGENT OR COMMON REPRESENTATIVE**

Next to each signature, indicate the name of the person signing and the capacity in which the person signs (if such capacity is not obvious from reading the request).

 <b>HOOVER, Kenley K.</b> Appointed Agent	
------------------------------------------------------------------------------------------------------------------------------------	--

For receiving Office use only	
1. Date of actual receipt of the purported international application:	2. Drawings: <input type="checkbox"/> received:  <input type="checkbox"/> not received:
3. Corrected date of actual receipt due to later but timely received papers or drawings completing the purported international application:	
4. Date of timely receipt of the required corrections under PCT Article 11(2):	
5. International Searching Authority (if two or more are competent): ISA /	6. <input type="checkbox"/> Transmittal of search copy delayed until search fee is paid

For International Bureau use only
Date of receipt of the record copy by the International Bureau:



This sheet is not part of and does not count as a sheet of the international application.

# PCT

## FEE CALCULATION SHEET

Annex to the Request

For receiving Office use only

International Application No.

Date stamp of the receiving Office

Applicant's or agent's  
file reference

PS956PCT

Applicant

Human Genome Sciences, Inc.

### CALCULATION OF PRESCRIBED FEES

1. TRANSMITTAL FEE . . . . . 240.00 [T]

2. SEARCH FEE . . . . . 700.00 [S]

International search to be carried out by ISA/US  
(If two or more International Searching Authorities are competent to carry out the international search, indicate the name of the Authority which is chosen to carry out the international search.)

3. INTERNATIONAL FEE

#### Basic Fee

Where item (b) of Box No. IX applies, enter Sub-total number of sheets } 862  
Where item (b) of Box No. IX does not apply, enter Total number of sheets }

[b1] first 30 sheets . . . . . 382.00 [b1]

[b2] 832 x 9 = 7,488.00 [b2]  
number of sheets fee per sheet  
in excess of 30

[b3] additional component (only if sequence listing part of description  
is filed in computer readable form under Section 801(a)(i), or  
both in that form and on paper, under Section 801(a)(ii)):

400 x                      =                      [b3]  
fee per sheet

Add amounts entered at b1, b2 and b3 and enter total at B . . . . . 7,870.00 [B]

#### Designation Fees

The international application contains 87 designations.

6 x 82 = 492.00 [D]  
number of designation fees amount of designation fee  
payable (maximum 6)

Add amounts entered at B and D and enter total at I . . . . . 8,362.00 [I]

(Applicants from certain States are entitled to a reduction of 75% of the international fee. Where the applicant is (or all applicants are) so entitled, the total to be entered at I is 25% of the sum of the amounts entered at B and D.)

4. FEE FOR PRIORITY DOCUMENT (if applicable) . . . . . 45.00 [P]

5. TOTAL FEES PAYABLE . . . . . 8,407.00

Add amounts entered at T, S, I and P, and enter total in the TOTAL box

TOTAL

☐ The designation fees are not paid at this time.

### MODE OF PAYMENT

☒ authorization to charge  
deposit account (see below)

☐ postal money order

☐ cash

☐ coupons

☐ cheque

☐ bank draft

☐ revenue stamps

☐ other (specify):

### AUTHORIZATION TO CHARGE (OR CREDIT) DEPOSIT ACCOUNT

(This mode of payment may not be available at all receiving Offices)

☒ Authorization to charge the total fees indicated above.

☒ (This check-box may be marked only if the conditions for deposit accounts  
of the receiving Office so permit) Authorization to charge any deficiency  
or credit any overpayment in the total fees indicated above.

☒ Authorization to charge the fee for priority document.

Receiving Office: RO/ US

Deposit Account No.: 08-3425

Date: March 26, 2002

Name: Kenley K Hoover

Signature: [Signature]



P.B 5818 - Patentlaan 2  
2280 HV Rijswijk (ZH)  
☎ +31 70 340 2040  
TX 31651 epo.nl  
FAX +31 70 340 3016

Europäisches  
Patentamt

Eingangs-  
stelle

European  
Patent Office

Receiving  
Section

Office européen  
des brevets

Section de  
Dépôt

VOSSIUS & PARTNER  
Siebertstrasse 4  
81675 München  
ALLEMAGNE

EINGEGANGEN  
Vossius & Partner

21. Jan. 2004

Frist  
bearb.:



R



09 5636 6025 5 DE

Datum/Date 19-01-2004

Zeichen/Ref./Ref.

H 2566 EP S3

Anmeldung Nr./Application No./Demande n°/Patent Nr./Patent No./Brevet n°.

02756084.6-2405

Anmelder/Applicant/Demandeur/Patentinhaber/Proprietor/Titulaire

Human Genome Sciences, Inc.

NOTIFICATION PURSUANT TO RULE 41(1), 111(2) EPC IN CONJUNCTION WITH  
ARTICLE 91(1) EPC

Your attention is drawn to the following deficiency in the above-  
identified European patent application:

[ ] The indication of the file number(s) of the previous application(s)  
from which priority is claimed is (are) missing.

[X] A copy of the previous application from which priority is claimed  
is missing. us 09/950,083 (12.09.01)

The copy must be certified as an exact copy of the previous  
application by the authority which received the previous applica-  
tion and shall be accompanied by a certificate issued by that  
authority stating the date of filing of the previous application.

Where multiple priorities are claimed, ALL copies must be filed  
within the time limit specified below.

In the event of failure to remedy the indicated deficiency within  
TWO MONTHS after notification of this communication, the right of  
priority will be lost for the application (Art. 91(3) EPC).

RECEIVING SECTION



REGISTERED LETTER

EPO Form 1111 03.00)

02756084.6 EXTI

PRI001

7006021 12/01/04

M02 005